top of page
  • Recruiting

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint

Updated: May 24, 2022


NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM


CyborD

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM


A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma


This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.


Sponsor

Canadian Myeloma Research Group


Location

Canada

 

ClinicalTrials.gov Identifier: NCT04786028


Official Title: A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma


First Posted: March 8, 2021


Click here to see details on ClinicalTrials.gov

 
 

Locations

Canada, Alberta

Canada, Manitoba

Canada, Newfoundland and Labrador

Canada, Nova Scotia

Canada, Ontario

Canada, Saskatchewan


Comentários


Posts Archive
bottom of page